Twist Bioscience Corporation’s Quiet Period Will Expire on December 10th (NASDAQ:TWST)

Twist Bioscience’s (NASDAQ:TWST) quiet period will expire on Monday, December 10th. Twist Bioscience had issued 5,000,000 shares in its IPO on October 31st. The total size of the offering was $70,000,000 based on an initial share price of $14.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

TWST has been the subject of several recent research reports. JPMorgan Chase & Co. initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set a “neutral” rating and a $27.00 target price for the company. Cowen initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set an “outperform” rating for the company. Finally, Robert W. Baird initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set an “outperform” rating for the company.

Shares of Twist Bioscience stock opened at $29.85 on Wednesday. Twist Bioscience has a 52 week low of $12.38 and a 52 week high of $33.72.

In other Twist Bioscience news, Director Keith Crandell bought 75,000 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was bought at an average price of $14.00 per share, for a total transaction of $1,050,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

TRADEMARK VIOLATION NOTICE: “Twist Bioscience Corporation’s Quiet Period Will Expire on December 10th (NASDAQ:TWST)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.com-unik.info/2018/12/05/twist-bioscience-corporations-quiet-period-will-expire-on-december-10th-nasdaqtwst.html.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Article: Dividend Stocks – Are They Right For You?

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit